Standard BioTools Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Standard BioTools Inc. (LAB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 63.98 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- Standard BioTools Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 68.34M shares, a 2.29% decline year-over-year.
- Standard BioTools Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 69.95M shares, a 8.79% decline year-over-year.
- Standard BioTools Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 76.68M shares.
- Standard BioTools Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-03-31 was 103.89M shares, a 277.96% increase year-over-year.
- Standard BioTools Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 63.72M shares, a 0.90% decline from fiscal 2024.
- Standard BioTools Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 64.30M shares, a 42.01% decline from fiscal 2023.
- Standard BioTools Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 110.88M shares, a 3.02% decline from fiscal 2022.
- Standard BioTools Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 114.34M shares, a 304.19% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 63.98M shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 68.34M shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 63.72M shares 10-K · filed 2026-03-16 | |||
| 2025-09-30 | 67.73M shares 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 65.51M shares 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 69.95M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 64.30M shares 10-K · filed 2026-03-16 | |||
| 2024-09-30 | 85.33M shares 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | 83.94M shares 10-Q · filed 2025-08-15 | |||
| 2024-03-31 | 76.68M shares 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 110.88M shares 10-K · filed 2026-03-16 | |||
| 2022-12-31 | 114.34M shares 10-K · filed 2023-03-14 | |||
| 2022-09-30 | 113.13M shares 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | 113.84M shares 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | 103.89M shares 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | 28.29M shares 10-K · filed 2023-03-14 | |||
| 2021-09-30 | 27.95M shares 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | 27.73M shares 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | 27.49M shares 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | 27.33M shares 10-K · filed 2022-03-08 | |||
| 2020-09-30 | 27.46M shares 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 29.63M shares 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | 30.34M shares 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | 27.36M shares 10-K · filed 2022-03-08 | |||
| 2019-09-30 | 6.26M shares 10-Q · filed 2019-11-08 | 6.26M shares 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | 5.46M shares 10-Q · filed 2019-08-07 | 5.46M shares 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | 5.80M shares 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | 25.06M shares 10-K · filed 2021-02-25 | |||
| 2018-09-30 | 25.13M shares 10-Q · filed 2019-11-08 | 25.13M shares 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | 25.74M shares 10-Q · filed 2019-08-07 | 25.74M shares 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | 24.86M shares 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | 7.10M shares 10-K · filed 2020-02-27 | |||
| 2017-09-30 | 7.34M shares 10-Q · filed 2018-11-06 | 7.34M shares 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | 8.13M shares 10-Q · filed 2018-08-08 | 8.13M shares 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | 8.68M shares 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | 8.22M shares 10-K · filed 2019-03-18 | |||
| 2016-09-30 | 8.54M shares 10-Q · filed 2017-11-07 | 8.54M shares 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | 8.43M shares 10-Q · filed 2017-08-08 | 8.43M shares 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | 8.51M shares 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | 7.50M shares 10-K · filed 2018-03-08 | |||
| 2015-09-30 | 7.44M shares 10-Q · filed 2016-11-09 | 7.44M shares 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | 7.41M shares 10-Q · filed 2016-08-09 | 7.41M shares 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | 7.54M shares 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | 7.33M shares 10-K · filed 2017-03-03 | |||
| 2014-09-30 | 7.50M shares 10-Q · filed 2015-11-09 | 7.50M shares 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | 7.57M shares 10-Q · filed 2015-08-10 | 7.57M shares 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | 7.53M shares 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | 3.43M shares 10-K · filed 2016-02-29 | |||
| 2013-09-30 | 3.63M shares 10-Q · filed 2014-11-06 | 3.63M shares 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | 3.73M shares 10-Q · filed 2014-08-04 | 3.73M shares 10-Q · filed 2014-08-04 | ||
| 2012-12-31 | 2.94M shares 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |